Join our daily newsletter At The Bell to receive exclusive market insights
- Pharmaceutical company Acrux (ACR) enters an exclusive commercial agreement with US-based Padagis for one of its products
- Under the agreement, Padagis will commercialise Acrux’s product and will be responsible for sales, distribution and coordination of manufacturing
- Both parties will share the profits generated from the product sales and the unnamed product is expected to launch in the US later this year
- Details on the product and plans for its launch are commercially sensitive and therefore haven’t been disclosed
- ACR shares are up 3.13 per cent and trading at 6.6 cents per share at 2:23 pm AEST
Pharmaceutical company Acrux (ACR) has entered into an exclusive commercial agreement with US-based Padagis for one of its products.
Padagis provides extended topical and other speciality pharmaceutical products with over 200 products on the market today.
Under the agreement, Padagis will be responsible for commercialising Acrux’s product, this will include sales, distribution and coordination of manufacturing.
Both parties will share the profits generated from the product sales.
Further details of the product and plans for its launch are commercially sensitive and therefore haven’t been disclosed yet.
The product is expected to launch in the US during the second half of the year. Acrux said further details on this will be released to the market at the appropriate time.
On the market, ACR shares were up 3.13 per cent and trading at 6.6 cents per share at 2:23 pm AEST.
